Effect of intravenous dose and schedule on cerebrospinal fluid pharmacokinetics of 5-fluorouracil in the monkey.

There is little information regarding the pharmacology of 5-fluorouracil (5-FUra) in the central nervous system (CNS), despite its role in the treatment of diseases with CNS metastases and recent reports of neurotoxicity. In this study, the plasma and cerebrospinal fluid (CSF) pharmacokinetics of 5-FUra were examined in a primate model. Following a bolus dose, the area under the concentration versus time curves for 5-FUra in CSF was 48% of the plasma area under the concentration versus time curves. For continuous infusion of 5-FUra, the area under the concentration versus time curves ratio for CSF:plasma was 20 or 11%, depending upon the infusion rate. The mechanism for variations in CSF exposure based upon the pattern of plasma delivery is consistent with local metabolism of 5-FUra in the CNS. These findings should be considered in the evaluation of delivery schedules which are intended to maximize drug delivery to the CNS and/or minimize neurotoxicity.

[1]  J. Ward,et al.  Time-dose relationships for 5-fluorouracil cytotoxicity against human epithelial cancer cells in vitro. , 1982, Cancer research.

[2]  T. N. Campbell,et al.  High-dose allopurinol modulation of 5-FU toxicity: phase I trial of an outpatient dose schedule. , 1982, Cancer treatment reports.

[3]  R. Floyd,et al.  Clearance of Continuously Infused 5-Fluorouracil in Adults Having Lung or Gastrointestinal Carcinoma with or without Hepatic Metastases , 1982, Drug intelligence & clinical pharmacy.

[4]  R. Kaplan,et al.  Neurotoxicity of antineoplastic drugs. , 1982, Seminars in oncology.

[5]  R. Floyd,et al.  Cerebrospinal fluid versus serum concentrations of 5-FU, allopurinol, and oxypurinol during treatment of metastatic brain cancer with 5-FU infusion, allopurinol, and radiation. , 1982, Cancer treatment reports.

[6]  J. Posner,et al.  Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patients , 1982, Cancer.

[7]  S. Howell,et al.  Modulation of 5‐fluorouracil toxicity by allopurinol in man , 1981, Cancer.

[8]  M. Boyd,et al.  A sensitive method for determination of 5-fluorouracil and 5-fluoro-2'-deoxyuridine in human plasma by high-pressure liquid chromatography. , 1980, Analytical biochemistry.

[9]  R. Dedrick,et al.  Nonlinear pharmacokinetic models for 5‐fluorouracil in man: Intravenous and intraperitoneal routes , 1980, Clinical pharmacology and therapeutics.

[10]  V. Vaitkevicius,et al.  Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. , 1980, Cancer research.

[11]  J. Rosenfeld,et al.  Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion. , 1978, British Journal of Cancer.

[12]  A. Ommaya,et al.  Chronic ventricular cerebrospinal fluid sampling, drug injections, and pressure monitoring using subcutaneous reservoirs in monkeys. , 1977, Neurosurgery.

[13]  R. Diasio,et al.  Pharmacokinetics of the fluoropyrimidines: implications for their clinical use. , 1976, Cancer treatment reviews.

[14]  H. Weiss,et al.  Neurotoxicity of commonly used antineoplastic agents (first of two parts). , 1974, The New England journal of medicine.

[15]  D. B. Tower,et al.  Kinetics of entry and distribution of 5-fluorouracil in cerebrospinal fluid and brain following intravenous injection in a primate. , 1973, Cancer research.

[16]  H. Koenig,et al.  The acute cerebellar syndrome in 5-fluorouracil chemotherapy: a manifestation of fluoroacetate intoxication. , 1970, Neurology.

[17]  D. Hutchison,et al.  The physiologic disposition of 5‐fluorouracil and 5‐fluoro‐2′‐deoxyuridine in man , 1964, Clinical pharmacology and therapeutics.

[18]  J. Byfield,et al.  Effect of intravenous dose and schedule on cerebrospinal fluid pharmacokinetics of 5-fluorouracil in the monkey. , 1985, Cancer Research.

[19]  R. Blasberg.  Pharmacokinetics and Metastatic Brain Tumor Chemotherapy , 1980 .

[20]  C. Heidelberger,et al.  Studies on Fluorinated Pyrimidines XVI. Metabolism of 5-Fluorouracil-2-C14 and 5-Fluoro-2′-deoxyuridine-2-C14 in Cancer Patients , 1963 .